IDH1 and IDH2 Mutations in Gliomas

Cited by (1,012)

Items 301–400 of 1,012

1. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma
   Andrey Korshunov, Jochen Meyer, David Capper, Arne Christians, Marc Remke, Hendrik Witt, Stefan Michael Pfister, Andreas von Deimling, Christian Johannes Hartmann · 2009 · Acta Neuropathologica
2. Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
   Kasthuri S. Kannan, Akiko Inagaki, Joachim Silber, Daniel J. Gorovets, Jianan Zhang, Edward R. Kastenhuber, Adriana Heguy, John H.J. Petrini, Timothy An-thy Chan, Jason T. Huse · 2012 · Oncotarget
3. Mechanisms driving the immunoregulatory function of cancer cells
   Antoinette van Weverwijk, Karin E. de Visser · 2023 · Nature reviews. Cancer
4. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
   Michael Jansen, Stephen S. F. Yip, David N. Louis · 2010 · The Lancet Neurology
5. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
   Jean‐Pierre Bayley, Henricus P. M. Kunst, Alberto Cascón, Maria Lourdes Sampietro, José Gaal, Esther Korpershoek, Adolfo Hinojar‐Gutiérrez, Henri J L M Timmers, Lies H. Hoefsloot, Mario A. J. A. Hermsen et al. · 2010 · The Lancet Oncology
6. Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies
   Sameer Agnihotri, Kelly E. Burrell, Amparo Wolf, Sharzhad Jalali, Cynthia E Hawkins, James T. Rutka, Gelareh Mohammed Zadeh · 2012 · Archivum Immunologiae et Therapiae Experimentalis
7. The Influence of Metabolism on Drug Response in Cancer
   Zaal, Esther A., Berkers, Celia R. · 2018 · Frontiers in Oncology
8. Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities
   Haruka Itakura, Achal Singh Achrol, Lex A. Mitchell, Joshua J. Loya, Tiffany Ting Liu, Erick M. Westbroek, Abdullah Hamid Feroze, Scott Rodriguez, Sebastian Echegaray, Tej Deepak Azad et al. · 2015 · Science Translational Medicine
9. Revisiting the TCA cycle: signaling to tumor formation
   Nuno Raimundo, Bora E. Baysal, Gerald S. Shadel · 2011 · Trends in Molecular Medicine
10. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma
    Felix Sahm, David Reuß, Christian Koelsche, David Capper, Jens Schittenhelm, Stephanie Heim, David Jones, Stefan Michael Pfister, Christel C. Herold‐Mende, Wolfgang Wick et al. · 2014 · Acta Neuropathologica
11. Signaling in Control of Cell Growth and Metabolism
    Patrick S. Ward, Craig B. Thompson · 2012 · Cold Spring Harbor Perspectives in Biology
12. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
    Felipe Javier Núñez, Flor Mendez, Padma Kadiyala, Mahmoud S. Alghamri, Masha G. Savelieff, María Belén Garcia-Fabiani, Santiago Haase, Carl Johannes Koschmann, Anda‐Alexandra Calinescu, Neha Kamran et al. · 2019 · Science Translational Medicine
13. Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development
    Hui Zong, Luis F. Parada, Suzanne J. Baker · 2015 · Cold Spring Harbor Perspectives in Biology
14. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
    Annie Im, Alison R. Sehgal, Martin P Carroll, Bruce Douglas Smith, Ayalew Tefferi, Daniel E. Johnson, Michael M. Boyiadzis · 2014 · Leukemia
15. TERT promoter mutations in primary and secondary glioblastomas
    Naosuke Nonoguchi, Takashi Ohta, Jieun Oh, Young-Ho Kim, Paul Kleihues, Hiroko Ohgaki · 2013 · Acta Neuropathologica
16. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
    Biqi Zhang, Ken Chang, Shakti H Ramkissoon, Shyam Kumar Tanguturi, Wenya Linda Bi, David A. Reardon, Keith Lloyd Ligon, Brian Michael Alexander, Patrick Yung Wen, Raymond Y. Huang · 2016 · Neuro-Oncology
17. Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme
    Pascal Olivier Zinn, Bhanu Majadan, Pratheesh Sathyan, Sanjay Kumar Singh, Sadhan Majumder, Ferenc Andras Jolesz, Rivka R. Colen · 2011 · PLoS ONE
18. Aberrant Signaling Pathways in Glioma
    Mitsutoshi Nakada, Daisuke Kita, Takuya Watanabe, Yutaka Hayashi, Lei Teng, Ilya V. Pyko, Jun‐ichiro Hamada · 2011 · Cancers
19. Mitochondria Targeting as an Effective Strategy for Cancer Therapy
    Poorva Ghosh, Chantal Vidal, Sanchareeka Dey, Zhang Li · 2020 · International Journal of Molecular Sciences
20. H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas
    Pathania, Manav, De Jay, Nicolas, Maestro, Nicola, Harutyunyan, Ashot S., Nitarska, Justyna, Pahlavan, Pirasteh, Henderson, Stephen, Mikael, Leonie G., Richard-Londt, Angela, Zhang, Ying et al. · 2017 · Cancer Cell
21. Low-Grade Gliomas
    Deborah Anne Forst, Brian Vala Nahed, Jay S. Loeffler, Tracy T. Batchelor · 2014 · The Oncologist
22. Mutations in IDH1 , IDH2 , and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
    Patrick J. Killela, Christopher J. Pirozzi, Patrick N Healy, Zachary J. Reitman, Eric Lipp, B. Ahmed Rasheed, Rui Ryan Yang, Bill H. Diplas, Zhaohui Wang, Paula K. Greer et al. · 2014 · Oncotarget
23. Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
    Chi Chun Wong, Ying Qian, Jun Qing Yu · 2017 · Oncogene
24. Using the molecular classification of glioblastoma to inform personalized treatment
    Adriana Olar, Kenneth Aldape · 2013 · The Journal of Pathology
25. Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management
    Yongzhi Wang, Tao Jiang · 2013 · Cancer Letters
26. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
    Sandro Santagata, Lívia S. Eberlin, Isaiah H. Norton, David Calligaris, Daniel R. Feldman, Jennifer L. Ide, Xiaohui Liu, Joshua S. Wiley, Matthew L. Vestal, Shakti H Ramkissoon et al. · 2014 · Proceedings of the National Academy of Sciences
27. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
    Sampath, Deepak, Zabka, Tanja S., Misner, Dinah L., O’Brien, Thomas, Dragovich, Peter S. · 2015 · Pharmacology & Therapeutics
28. Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics
    Yoon Seong Choi, Sohi Bae, Jong Hee Chang, Seok‐Gu Kang, Se Hoon Kim, Jinna Kim, Tyler Hyungtaek Rim, Seung Hong Choi, Rajan Jain, Seung‐Koo Lee · 2020 · Neuro-Oncology
29. DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
    Brock C. Christensen, Ashley A. Smith, Shichun Zheng, Devin C. Koestler, Eugene Andres Houseman, Carmen J. Marsit, Joseph Leo Wiemels, Heather H. Nelson, Margaret Rita Karagas, Margaret Wrensch et al. · 2010 · JNCI Journal of the National Cancer Institute
30. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
    Kortüm, K. Martin, Mai, Elias K., Hanafiah, Nur H., Shi, Chang-Xi, Zhu, Yuan-Xiao, Bruins, Laura, Barrio, Santiago, Jedlowski, Patrick, Merz, Maximilian, Xu, Jing et al. · 2016 · Blood
31. Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
    Nicholas S. Akins, Tanner C. Nielson, Hoang V. Le · 2018 · Current Topics in Medicinal Chemistry
32. TET proteins and the control of cytosine demethylation in cancer
    Laurianne Scourzic, Enguerran Mouly, Olivier Bernard · 2015 · Genome Medicine
33. IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma
    Chao Wang, Timothy W. McKeithan, Qiang Gong, Weiwei Zhang, Alyssa C. Bouska, Andreas Rosenwald, Randy D. Gascoyne, Xiwei Wu, Jinhui Wang, Zahid Muhammad et al. · 2015 · Blood
34. Defects in mitochondrial metabolism and cancer
    Edoardo Gaude, Christian Frezza · 2014 · Cancer & Metabolism
35. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
    Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu et al. · 2016 · Acta Neuropathologica Communications
36. Targeting Epigenetics in Cancer
    Richard Lynn Bennett, Jonathan D. Licht · 2017 · The Annual Review of Pharmacology and Toxicology
37. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision
    Takashi Komori · 2017 · Neurologia medico-chirurgica
38. Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
    Joshua David Schiffman, J. Graeme Hodgson, Scott R. VandenBerg, Patrick Flaherty, Mei‐Yin C. Polley, Mamie Yu, Paul Graham Fisher, David H. Rowitch, James M. Ford, Mitchel Stuart Berger et al. · 2010 · Cancer Research
39. Mutational Heterogeneity in Human Cancers: Origin and Consequences
    Jesse J. Salk, Edward Fox, Lawrence A. Loeb · 2009 · Annual Review of Pathology Mechanisms of Disease
40. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
    Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel K. McBrayer, Michael Weller, Timothy Francis Cloughesy, Jana Portnow, Ovidiu C. Andronesi, Jill S. Barnholtz‐Sloan, Brigitta G. Baumert, Mitchel Stuart Berger et al. · 2022 · Neuro-Oncology
41. Survival Outcomes and Prognostic Factors in Glioblastoma
    Nicholas Fraser Brown, Diego Ottaviani, John Tazare, John Gregson, Neil D. Kitchen, Sebastian Brandner, Naomi L. Fersht, Paul James Mulholland · 2022 · Cancers
42. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
    Olivier Kosmider, Véronique Gelsi‐Boyer, L Slama, François Dreyfus, Odile Beyne‐Rauzy, Bruno Quesnel, Mathilde Hunault, Bohrane Slama, Norbert Vey, C. Lacombe et al. · 2010 · Leukemia
43. Pleomorphic Xanthoastrocytoma: Natural History and Long‐Term Follow‐Up
    Cristiane M. Ida, Fausto J. Rodríguez, Peter C. Burger, Alissa A. Caron, Sarah M. Jenkins, Grant M. Spears, Dawn Aranguren, Daniel Honore Lachance, Caterina Giannini · 2014 · Brain Pathology
44. Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses
    Inseok Choi, Hyewon Son, Jea-Hyun Baek · 2021 · Life
45. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Ingo K. Mellinghoff, Min Lu, Patrick Yung Wen, Jennie Webster Taylor, Elizabeth Anne Maher, Isabel Arrillaga‐Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun et al. · 2023 · Nature Medicine
46. NADP+-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance
    Li, Feng, He, Xiadi, Ye, Dingwei, Lin, Yan, Yu, Hongxiu, Yao, Cuifang, Huang, Lei, Zhang, Jianong, Wang, Fang, Xu, Sha et al. · 2015 · Molecular Cell
47. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
    Benjamin R. Kipp, Jesse S. Voss, Sarah E. Kerr, Emily G. Barr Fritcher, Rondell Patrell Graham, Lizhi Zhang, William Edward Highsmith, Jun Zhang, Lewis Rowland Roberts, Gregory James Gores et al. · 2012 · Human Pathology
48. Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas
    Mathias Kunz, Niklas Thon, Sabina Eigenbrod, Christian Johannes Hartmann, Rupert Egensperger, Jochen Wolfgang Herms, Julia Geisler, Christian Jean la Fougère, Juergen Lutz, Jennifer Linn et al. · 2011 · Neuro-Oncology
49. Mitochondrial dysfunction in neurodegenerative diseases and cancer
    Michelle Barbi de Moura, Lucas Santana‐Santos, Bennett Van Houten · 2010 · Environmental and Molecular Mutagenesis
50. Cancer metabolism: Key players in metabolic reprogramming
    Tomoyoshi Soga · 2012 · Cancer Science
51. PKM2, a Central Point of Regulation in Cancer Metabolism
    Nicholas Wong, Jason De Melo, Damu Tang · 2013 · International Journal of Cell Biology
52. Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
    Terrie Ellen Taylor, Frank B. Furnari, Webster K. Cavenee · 2012 · Current Cancer Drug Targets
53. NFKBIA Deletion in Glioblastomas
    Markus Bredel, Denise M. Scholtens, Ajay K. Yadav, Angel A. Alvarez, Jaclyn J. Renfrow, James P. Chandler, Irene L.Y. Yu, Maria Stella Carro, Fangping Dai, Michael J. Tagge et al. · 2010 · New England Journal of Medicine
54. Wild-type and mutated IDH1/2 enzymes and therapy responses
    Remco Jurriaan Molenaar, Jaroslaw Pawel Maciejewski, Johanna W. Wilmink, Cornelis J.F. Van Noorden · 2018 · Oncogene
55. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
    Ye, Dan, Guan, Kun-Liang, Xiong, Yue · 2018 · Trends in Cancer
56. Emerging Applications of Artificial Intelligence in Neuro-Oncology
    Jeffrey D. Rudie, Andreas M. Rauschecker, Robert Nick Bryan, Christos A. Davatzikos, Suyash Mohan · 2019 · Radiology
57. Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
    Katharina Wagner, Frédérik Damm, Gudrun Göhring, Kerstin Görlich, Michael Heuser, Irina Schäfer, Oliver Gerhard Ottmann, Michael Lübbert, Wolfgang F.W. Heit, Lothar Kanz et al. · 2010 · Journal of Clinical Oncology
58. Cancer epigenetics in clinical practice
    Verónica Dávalos, Manel Esteller · 2022 · CA A Cancer Journal for Clinicians
59. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine
    Turcan, Sevin, Fabius, Armida W. M., Borodovsky, Alexandra, Pedraza, Alicia, Brennan, Cameron, Huse, Jason, Viale, Agnes, Riggins, Gregory J., Chan, Timothy A. · 2013 · Oncotarget
60. Glutamine Metabolism in Cancer
    Ting Li, Anne Le · 2018 · Advances in experimental medicine and biology
61. Molecular Classification of Low-Grade Diffuse Gliomas
    Young-Ho Kim, Sumihito Nobusawa, Michel Guy André Mittelbronn, Werner Paulus, Benjamin Brokinkel, Kathy Keyvani, Ulrich Sure, Karsten Henning Wrede, Yoichi Nakazato, Yuko Tanaka et al. · 2010 · American Journal Of Pathology
62. Genome-wide association study of glioma and meta-analysis
    Preetha Rajaraman, Beatrice S. Melin, Zhaoming Wang, Roberta McKean‐Cowdin, Dominique S. Michaud, SOPHIA S WANG, Melissa L. Bondy, Richard S. Houlston, Robert Brian Jenkins, Margaret Wrensch et al. · 2012 · Human Genetics
63. Modern Brain Tumor Imaging
    Marc C. Mabray, Ramon Barajas, Soonmee Cha · 2015 · Brain Tumor Research and Treatment
64. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
    Craig Horbinski, Burt Nabors, Jana Portnow, Joachim M. Baehring, Ankush Bhatia, Orin G. Bloch, Steven S. Brem, Nicholas Arthur Butowski, Donald Maurice Cannon, Samuel T. Chao et al. · 2023 · Journal of the National Comprehensive Cancer Network
65. Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma
    Jing Li, Meihua Wang, Minhee Won, Edward G. Shaw, Christopher T. Coughlin, Walter John Curran, Minesh P. Mehta · 2010 · International Journal of Radiation Oncology*Biology*Physics
66. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling
    Xudong Fu, R Chin, Laurent Vergnes, Heejun Hwang, Gang Deng, Yanpeng Xing, Melody Y. Pai, Sichen Li, Lisa H. Ta, Farbod Fazlollahi et al. · 2015 · Cell Metabolism
67. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
    Wolfgang Wick, Christoph Meisner, Bettina Hentschel, Michael Platten, Alissa Schilling, Benedikt Wiestler, Michael Sabel, Susanne Koeppen, Ralf Ketter, Markus Weiler et al. · 2013 · Neurology
68. Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells
    Fukushi Abekura, Hee-Do Kim, Yu‐Chan Chang, Cheorl‐Ho Kim · 2022 · International Journal of Molecular Sciences
69. TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation
    Luisa Cimmino, Omar Ibrahim Abdel-Wahab, Ross L. Levine, Iannis Aifantis · 2011 · Cell stem cell
70. ATP-Dependent Lon Protease Controls Tumor Bioenergetics by Reprogramming Mitochondrial Activity
    Quirós, Pedro M., Español, Yaiza, Acín-Pérez, Rebeca, Rodríguez, Francisco, Bárcena, Clea, Watanabe, Kenta, Calvo, Enrique, Loureiro, Marta, Fernández-García, M. Soledad, Fueyo, Antonio et al. · 2014 · Cell Reports
71. Molecular subclassification of diffuse gliomas: Seeing order in the chaos
    Jason T. Huse, HEIDI S. PHILLIPS, Cameron Walter Brennan · 2011 · Glia
72. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
    Danielle Golub, Nishanth S. Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram Sandaldjian Modrek, Dimitris G. Placantonakis · 2019 · Frontiers in Oncology
73. Toward precision medicine in glioblastoma: the promise and the challenges
    Michael D. Prados, Sara Ann Byron, Nhan L. Tran, Joanna J. Phillips, Annette M. Molinaro, Keith Lloyd Ligon, Patrick Yung Wen, John G. Kuhn, Ingo K. Mellinghoff, John de Groot et al. · 2015 · Neuro-Oncology
74. The role of neuropathology in the management of patients with diffuse low grade glioma
    Daniel P. Cahill, Andrew Edward Sloan, Brian Vala Nahed, Kenneth Aldape, David N. Louis, Timothy Charles Ryken, Steven N. Kalkanis, Jeffrey J. Olson · 2015 · Journal of Neuro-Oncology
75. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism
    Chang, Soojeong, Yim, Sujin, Park, Hyunsung · 2019 · Experimental & Molecular Medicine
76. Oligodendroglioma: pathology, molecular mechanisms and markers
    Pieter Wesseling, Martin J. van den Bent, Arie Perry · 2015 · Acta Neuropathologica
77. Regulatory mechanisms of hypoxia‐inducible factor 1 activity: Two decades of knowledge
    Sho Koyasu, Minoru Kobayashi, Yökö Gotö, Masahiro Hiraoka, Hiroshi Harada · 2017 · Cancer Science
78. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
    James J. Harding, Maeve Aine Lowery, Alan H. Shih, Juan M. Schvartzman, Shengqi Hou, Christopher A. Famulare, Minal A. Patel, Mikhail Roshal, Richard K. G. Do, Ahmet Zehir et al. · 2018 · Cancer Discovery
79. Molecular and Genomic Alterations in Glioblastoma Multiforme
    Crespo, Ines, Vital, Ana Louisa, Gonzalez-Tablas, María, Patino, María del Carmen, Otero, Alvaro, Lopes, María Celeste, de Oliveira, Catarina, Domingues, Patricia, Orfao, Alberto, Tabernero, Maria Dolores · 2015 · The American Journal of Pathology
80. Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis
    Kenji Ohshima, Eiichi Morii · 2021 · Metabolites
81. Chirality in Light–Matter Interaction
    Andrew R. Lininger, Giovanna Palermo, Alexa Guglielmelli, Giuseppe Nicoletta, Madhav Goel, Michael Hinczewski, Giuseppe Strangi · 2022 · Advanced Materials
82. The cellular origin for malignant glioma and prospects for clinical advancements
    Hui Zong, Roel G.W. Verhaak, Peter Canoll · 2012 · Expert Review of Molecular Diagnostics
83. IDH Mutation in Glioma
    Zorbey T. Turkalp, Jason Karamchandani, Sunit Das · 2014 · JAMA Neurology
84. Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
    Kloosterhof, Nanne K, Bralten, Linda BC, Dubbink, Hendrikus J, French, Pim J, van den Bent, Martin J · 2011 · The Lancet Oncology
85. Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
    Nicolas Boissel, Olivier Nibourel, Aline Renneville, Claude Gardin, Oumédaly Reman, Nathalie Contentin, Dominique Bordessoule, Cécile Pautas, Thierry de Revel, Bruno Quesnel et al. · 2010 · Journal of Clinical Oncology
86. Hallmarks of cancer—the new testament
    Sasi S. Senga, Richard Philip Grose · 2021 · Open Biology
87. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
    de Botton, Stephane, Mondesir, Johanna, Willekens, Christophe, Touat, Mehdi · 2016 · Journal of Blood Medicine
88. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
    Daniel N. Cagney, Joohee Sul, Raymond Y. Huang, Keith Lloyd Ligon, Patrick Yung Wen, Brian Michael Alexander · 2017 · Neuro-Oncology
89. Oncometabolites in renal cancer
    Cissy Yong, Grant Duncan Stewart, Christian Frezza · 2019 · Nature Reviews Nephrology
90. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
    Bell, Erica H., Zhang, Peixin, Shaw, Edward G., Buckner, Jan C., Barger, Geoffrey R., Bullard, Dennis E., Mehta, Minesh P., Gilbert, Mark R., Brown, Paul D., Stelzer, Keith J. et al. · 2020 · Journal of Clinical Oncology
91. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence
    Şevin Turcan, Vladimir Makarov, Julián Taranda, Yuxiang Wang, Armida W. M. Fabius, Wei Wu, Yupeng Zheng, Nour El-Amine, Sara Haddock, Gouri J. Nanjangud et al. · 2017 · Nature Genetics
92. Temozolomide-associated hypermutation in gliomas
    Serah Choi, Yao Yu, Matthew Grimmer, Michael Traut Wahl, Susan Marina Chang, J Costello · 2018 · Neuro-Oncology
93. Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
    Yoshihiro Hayashi, Asumi Yokota, Hironori Harada, Gang Huang · 2019 · Cancer Science
94. Comparison of glioblastoma (GBM) molecular classification methods
    Eunjee Lee, Raymund L.M. Yong, Patrick J. Paddison, Jun Zhu · 2018 · Seminars in Cancer Biology
95. The molecular landscape of glioma in patients with Neurofibromatosis 1
    Fulvio D’Angelo, Michele Ceccarelli, Tala, Luciano Garofano, Jing Zhang, Veroniquè Frattini, Francesca Pia Caruso, Genevieve Lewis, Kristin D. Alfaro-Munoz, Luc Bauchet et al. · 2018 · Nature Medicine
96. Adult IDH wild-type lower-grade gliomas should be further stratified
    Abudumijit Aibaidula, Aden Ka‐Yin Chan, Zhifeng Shi, Yanxi Li, Ruiqi Zhang, Rui Yang, Kay Ka‐Wai Li, Nellie Yuk‐Fei Chung, Yu Yao, Liangfu Zhou et al. · 2017 · Neuro-Oncology
97. Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria
    Luke W. Thomas, Margaret A. Ashcroft · 2019 · Cellular and Molecular Life Sciences
98. Metabolic enzymes as oncogenes or tumor suppressors
    Thompson, Craig B. · 2009 · New England Journal of Medicine
99. Molecular pathology of tumors of the central nervous system
    Bjarne Winther Kristensen, Loudy P. Priesterbach-Ackley, Jeanette Krogh Petersen, Pieter Wesseling · 2019 · Annals of Oncology
100. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
     Audra N. Boscoe, Catherine Rolland, Robin Kate Kelley · 2019 · Journal of Gastrointestinal Oncology